Table 1

Patient characteristics for year 1 and year 2 completers according to number of ranibizumab injections received during year 1 (<5, 5–7, >7 injections) and over the 2-year period (<10, 10–14, >14 injections)

	Year 1				Year 2
Injections	<5	5–7	>7	All	<10	10–14	>14	All
Patients, n	714	621	360	1695	697	298	189	1184
Age at start of therapy (%),§
<65 years	8	6	9	8†	8	5	10	7*
≥65–<75 years	20	26	29	24†	21	27	30	24*
≥75 years	70	66	60	67†	70	66	58	67*
Age (years), mean	77.4	76.9	76.0	76.9*	77.3	77.2	75.6	77*
Sex, %
Male	37	38	39	38	36	39	42	38
Female	63	62	61	62	64	61	58	62
Reimbursement type (%),§,¶
Individual	12	12	5	11‡	10	7	2	8‡
National standard	67	72	85	73‡	70	78	88	75‡
Separate contract	3	0	0	1‡	2	1	0	1‡
Independent	14	10	7	11‡	13	10	5	11‡
Patient	0	0	0	0‡	0	0	0	0‡
Other	1	0	0	1‡	1	0	1	1‡
Baseline visual acuity score, mean	58.3	57	54.1	56.9†	57.7	58.5	53	57.2†

*p<0.05; †p<0.01; ‡p<0.001 between groups (p value was derived from analysis of variance for continuous variables and χ² test for categorical variables).
^§Data missing for some patients.
^¶Reimbursement granted for patient independently of how often treatment was provided.